Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cardiovascular Diabetology
Published in: Cardiovascular Diabetology 1/2023

Open Access 01-12-2023 | Coronary Heart Disease | Review

Intensified glycemic control by HbA1c for patients with coronary heart disease and Type 2 diabetes: a review of findings and conclusions

Authors: Jingyang Chen, Dong Yin, Kefei Dou

Published in: Cardiovascular Diabetology | Issue 1/2023

Login to get access

Abstract

The occurrence and development of coronary heart disease (CHD) are closely linked to fluctuations in blood glucose levels. While the efficacy of intensified treatment guided by HbA1c levels remains uncertain for individuals with diabetes and CHD, this review summarizes the findings and conclusions regarding HbA1c in the context of CHD. Our review showed a curvilinear correlation between regulated level of HbA1c and therapeutic effectiveness of intensified glycemic control among patients with type 2 diabetes and coronary heart disease. It is necessary to optimize the dynamic monitoring indicators of HbA1c, combine genetic profiles, haptoglobin phenotypes for example and select more suitable hypoglycemic drugs to establish more appropriate glucose-controlling guideline for patients with CHD at different stage of diabetes.
Literature
1.
Global regional. National age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the global burden of Disease Study 2017. Lancet. 2018;392(10159):1736–88.CrossRef
2.
Global regional. National disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the global burden of Disease Study 2017. Lancet. 2018;392(10159):1859–922.CrossRef
3.
Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global Burden of Cardiovascular Diseases and Risk factors, 1990–2019: Update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982–3021.PubMedPubMedCentralCrossRef
4.
Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, et al. Heart Disease and Stroke Statistics-2023 update: a Report from the American Heart Association. Circulation. 2023;147(8):e93–e621.PubMedCrossRef
5.
Zhao D, Liu J, Wang M, Zhang X, Zhou M. Epidemiology of cardiovascular disease in China: current features and implications. Nat Rev Cardiol. 2019;16(4):203–12.PubMedCrossRef
6.
Bommer C, Heesemann E, Sagalova V, Manne-Goehler J, Atun R, Bärnighausen T, et al. The global economic burden of diabetes in adults aged 20–79 years: a cost-of-illness study. Lancet Diabetes Endocrinol. 2017;5(6):423–30.PubMedCrossRef
7.
Huisman TH, Martis EA, Dozy A. Chromatography of hemoglobin types on carboxymethylcellulose. J Lab Clin Med. 1958;52(2):312–27.PubMed
8.
Allen DW, Schroeder W, Balog J. Observations on the chromatographic heterogeneity of normal adult and fetal human hemoglobin: a study of the effects of crystallization and chromatography on the heterogeneity and isoleucine content. J Am Chem Soc. 1958;80(7):1628–34.CrossRef
9.
Bookchin RM, Gallop PM. Structure of hemoglobin AIc: nature of the N-terminal beta chain blocking group. Biochem Biophys Res Commun. 1968;32(1):86–93.PubMedCrossRef
10.
Rahbar S, Blumenfeld O, Ranney HM. Studies of an unusual hemoglobin in patients with diabetes mellitus. Biochem Biophys Res Commun. 1969;36(5):838–43.PubMedCrossRef
11.
Koenig RJ, Peterson CM, Jones RL, Saudek C, Lehrman M, Cerami A. Correlation of glucose regulation and hemoglobin AIc in diabetes mellitus. N Engl J Med. 1976;295(8):417–20.PubMedCrossRef
12.
Kilpatrick ES, Rigby AS, Atkin SL. Variability in the relationship between mean plasma glucose and HbA1c: implications for the assessment of glycemic control. Clin Chem. 2007;53(5):897–901.PubMedCrossRef
13.
14.
Nathan DM, Singer DE, Hurxthal K, Goodson JD. The clinical information value of the glycosylated hemoglobin assay. N Engl J Med. 1984;310(6):341–6.PubMedCrossRef
15.
Wu T, Dorn JP, Donahue RP, Sempos CT, Trevisan M. Associations of serum C-reactive protein with fasting insulin, glucose, and glycosylated hemoglobin: the Third National Health and Nutrition Examination Survey, 1988–1994. Am J Epidemiol. 2002;155(1):65–71.PubMedCrossRef
16.
Sen S, Kar M, Roy A, Chakraborti AS. Effect of nonenzymatic glycation on functional and structural properties of hemoglobin. Biophys Chem. 2005;113(3):289–98.PubMedCrossRef
17.
Kar M, Chakraborti AS. Release of iron from haemoglobin–a possible source of free radicals in diabetes mellitus. Indian J Exp Biol. 1999;37(2):190–2.PubMed
18.
White CR, Frangos JA. The shear stress of it all: the cell membrane and mechanochemical transduction. Philos Trans R Soc Lond B Biol Sci. 2007;362(1484):1459–67.PubMedPubMedCentralCrossRef
19.
Prasad K. Does HbA1cc play a role in the Development of Cardiovascular Diseases? Curr Pharm Des. 2018;24(24):2876–82.PubMedCrossRef
20.
Nathan DM, Turgeon H, Regan S. Relationship between glycated haemoglobin levels and mean glucose levels over time. Diabetologia. 2007;50(11):2239–44.PubMedPubMedCentralCrossRef
21.
Yudkin JS, Richter B, Gale EA. Intensified glucose control in type 2 diabetes—whose agenda? The Lancet. 2011;377(9773):1220–2.CrossRef
22.
Simova II, Denchev SV, Dimitrov SI, Ivanova R. Endothelial function in patients with and without diabetes mellitus with different degrees of coronary artery stenosis. J Clin Ultrasound. 2009;37(1):35–9.PubMedCrossRef
23.
Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373(9677):1765–72.PubMedCrossRef
24.
Zhang Y, Hu G, Yuan Z, Chen L. Glycosylated hemoglobin in relationship to cardiovascular outcomes and death in patients with type 2 diabetes: a systematic review and meta-analysis. PLoS ONE. 2012;7(8):e42551.PubMedPubMedCentralCrossRef
25.
Won KB, Han D, Lee JH, Lee SE, Sung JM, Choi SY, et al. Impact of optimal glycemic control on the progression of coronary artery calcification in asymptomatic patients with diabetes. Int J Cardiol. 2018;266:250–3.PubMedCrossRef
26.
Laiteerapong N, Ham SA, Gao Y, Moffet HH, Liu JY, Huang ES, et al. The legacy effect in type 2 diabetes: impact of early glycemic control on future complications (the Diabetes & Aging Study). Diabetes Care. 2019;42(3):416–26.PubMedCrossRef
27.
Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal T, Hemmingsen C, et al. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ. 2011;343:d6898.PubMedPubMedCentralCrossRef
28.
Smith SC Jr, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, et al. AHA/ACCF secondary Prevention and Risk Reduction Therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011;124(22):2458–73.PubMedCrossRef
29.
Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255–323.PubMedCrossRef
30.
Chen S, Shen Y, Liu YH, Dai Y, Wu ZM, Wang XQ, et al. Impact of glycemic control on the association of endothelial dysfunction and coronary artery disease in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2021;20(1):64.PubMedPubMedCentralCrossRef
31.
6. Glycemic targets: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44(Suppl 1):73–s84.
32.
Menon V, Kumar A, Patel DR, John JS, Wolski KE, McErlean E, et al. Impact of Baseline Glycemic Control on residual Cardiovascular risk in patients with diabetes Mellitus and high-risk vascular disease treated with statin therapy. J Am Heart Assoc. 2020;9(1):e014328.PubMedCrossRef
33.
Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone clinical trial in macroVascular events): a randomised controlled trial. Lancet. 2005;366(9493):1279–89.PubMedCrossRef
34.
Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–72.PubMedCrossRef
35.
Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129–39.PubMedCrossRef
36.
Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–59.PubMedCrossRef
37.
Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, Goff DC Jr, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011;364(9):818–28.PubMedCrossRef
38.
Tian J, Ohkuma T, Cooper M, Harrap S, Mancia G, Poulter N, et al. Effects of Intensive Glycemic Control on Clinical Outcomes among patients with type 2 diabetes with different levels of Cardiovascular Risk and Hemoglobin A(1c) in the ADVANCE trial. Diabetes Care. 2020;43(6):1293–9.PubMedCrossRef
39.
Hayward RA, Reaven PD, Emanuele NV. Follow-up of Glycemic Control and Cardiovascular Outcomes in type 2 diabetes. N Engl J Med. 2015;373(10):978.PubMed
40.
Reaven PD, Emanuele NV, Wiitala WL, Bahn GD, Reda DJ, McCarren M, et al. Intensive glucose control in patients with type 2 diabetes – 15-Year follow-up. N Engl J Med. 2019;380(23):2215–24.PubMedPubMedCentralCrossRef
41.
Corpus RA, George PB, House JA, Dixon SR, Ajluni SC, Devlin WH, et al. Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention. J Am Coll Cardiol. 2004;43(1):8–14.PubMedCrossRef
42.
Hwang JK, Lee SH, Song YB, Ahn J, Carriere K, Jang MJ et al. Glycemic Control Status after Percutaneous Coronary intervention and long-term clinical outcomes in patients with type 2 diabetes Mellitus. Circ Cardiovasc Interv. 2017;10(4).
43.
Kassaian SE, Goodarzynejad H, Boroumand MA, Salarifar M, Masoudkabir F, Mohajeri-Tehrani MR, et al. Glycosylated hemoglobin (HbA1c) levels and clinical outcomes in diabetic patients following coronary artery stenting. Cardiovasc Diabetol. 2012;11:82.PubMedPubMedCentralCrossRef
44.
Ike A, Nishikawa H, Shirai K, Mori K, Kuwano T, Fukuda Y, et al. Impact of glycemic control on the clinical outcome in diabetic patients with percutaneous coronary intervention–from the FU-registry. Circ J. 2011;75(4):791–9.PubMedCrossRef
45.
Park J, Han JK, Chang M, Ki YJ, Kang J, Yang HM et al. Impact of intensive glucose control in patients with diabetes Mellitus undergoing percutaneous coronary intervention: 3-Year clinical outcomes. J Clin Med. 2020;9(8).
46.
Robich MP, Iribarne A, Leavitt BJ, Malenka DJ, Quinn RD, Olmstead EM, et al. Intensity of Glycemic Control affects long-term survival after coronary artery bypass graft surgery. Ann Thorac Surg. 2019;107(2):477–84.PubMedCrossRef
47.
Bardia A, Khabbaz K, Mueller A, Mathur P, Novack V, Talmor D, et al. The Association between Preoperative Hemoglobin A1C and postoperative glycemic variability on 30-Day major adverse outcomes following isolated cardiac valvular surgery. Anesth Analg. 2017;124(1):16–22.PubMedCrossRef
48.
Halkos ME, Lattouf OM, Puskas JD, Kilgo P, Cooper WA, Morris CD, et al. Elevated preoperative hemoglobin A1c level is associated with reduced long-term survival after coronary artery bypass surgery. Ann Thorac Surg. 2008;86(5):1431–7.PubMedCrossRef
49.
Abu Tailakh M, Ishay SY, Awesat J, Poupko L, Sahar G, Novack V. Hemoglobin A1c in patients with diabetes Predict Long-Term Mortality following coronary artery surgery. J Clin Med. 2021;10(12).
50.
Deo S, Sundaram V, Sheikh MA, Sahadevan J, Selvaganesan P, Madan Mohan SK, et al. Pre-operative glycaemic control and long-term survival in diabetic patients after coronary artery bypass grafting. Eur J Cardiothorac Surg. 2021;60(5):1169–77.PubMedCrossRef
51.
Turgeon RD, Koshman SL, Youngson E, Pearson GJ. Association between Hemoglobin A1c and major adverse coronary events in patients with diabetes following coronary artery bypass surgery. Pharmacotherapy. 2020;40(2):116–24.PubMedCrossRef
52.
You H, Hou X, Zhang H, Li X, Feng X, Qian X, et al. Effect of glycemic control and glucose fluctuation on in-hospital adverse outcomes after on-pump coronary artery bypass grafting in patients with diabetes: a retrospective study. Diabetol Metab Syndr. 2023;15(1):20.PubMedPubMedCentralCrossRef
53.
Bonora E, Willeit J, Kiechl S, Oberhollenzer F, Egger G, Bonadonna R, et al. U-shaped and J-shaped relationships between serum insulin and coronary heart disease in the general population. The Bruneck Study. Diabetes Care. 1998;21(2):221–30.PubMedCrossRef
54.
Plakht Y, Gilutz H, Shiyovich A. Changes over Time in Hemoglobin A1C (HbA(1 C)) levels Predict Long-Term Survival following Acute myocardial infarction among patients with diabetes Mellitus. J Clin Med. 2021;10(15).
55.
Funamizu T, Iwata H, Nishida Y, Miyosawa K, Doi S, Chikata Y, et al. Increased risk of cardiovascular mortality by strict glycemic control (pre-procedural HbA1c < 6.5%) in japanese medically-treated diabetic patients following percutaneous coronary intervention: a 10-year follow-up study. Cardiovasc Diabetol. 2020;19(1):21.PubMedPubMedCentralCrossRef
56.
Wang J, Yan G, Qiao Y, Wang D, Ma G, Tang C. Different levels of glycosylated hemoglobin influence severity and long-term prognosis of coronary heart disease patients with stent implantation. Exp Ther Med. 2015;9(2):361–6.PubMedCrossRef
57.
Yang T, Fu P, Chen J, Fu X, Xu C, Liu X, et al. Increased risk of adverse cardiovascular events by strict glycemic control after percutaneous coronary intervention (HbA1c < 6.5% at 2 years) in type 2 diabetes mellitus combined with acute coronary syndrome: a 5-years follow-up study. Curr Med Res Opin. 2021;37(9):1517–28.PubMedCrossRef
58.
McAlister FA, Zheng Y, Westerhout CM, Buse JB, Standl E, McGuire DK, et al. Association between glycated haemoglobin levels and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the TECOS randomized clinical trial. Eur J Heart Fail. 2020;22(11):2026–34.PubMedCrossRef
59.
Liu L, Ye J, Ying M, Li Q, Chen S, Wang B, et al. The U-Shape relationship between Glycated Hemoglobin Level and Long-Term all-cause Mortality among patients with coronary artery disease. Front Cardiovasc Med. 2021;8:632704.PubMedPubMedCentralCrossRef
60.
Baber U, Azzalini L, Masoomi R, Johal G, Barman N, Sweeny J, et al. Hemoglobin A(1c) and Cardiovascular Outcomes following percutaneous coronary intervention: insights from a large Single-Center Registry. JACC Cardiovasc Interv. 2021;14(4):388–97.PubMedCrossRef
61.
Choi IJ, Choo EH, Kim HJ, Lim S, Moon D, Lee KY, et al. J-curve relationship between long term glycemic control and mortality in diabetic patients with acute myocardial infarction undergoing percutaneous coronary intervention. Cardiovasc Diabetol. 2021;20(1):234.PubMedPubMedCentralCrossRef
62.
Östgren CJ, Sundström J, Svennblad B, Lohm L, Nilsson PM, Johansson G. Associations of HbA1c and educational level with risk of cardiovascular events in 32,871 drug-treated patients with type 2 diabetes: a cohort study in primary care. Diabet Med. 2013;30(5):e170–7.PubMedPubMedCentralCrossRef
63.
Li L, Lip GYH, Li S, Adachi JD, Thabane L, Li G. Associations between glycated hemoglobin and the risks of incident cardiovascular diseases in patients with gout. Cardiovasc Diabetol. 2022;21(1):133.PubMedPubMedCentralCrossRef
64.
Gore MO, McGuire DK. A test in Context: Hemoglobin A(1c) and Cardiovascular Disease. J Am Coll Cardiol. 2016;68(22):2479–86.PubMedCrossRef
65.
Ghouse J, Isaksen JL, Skov MW, Lind B, Svendsen JH, Kanters JK, et al. Effect of diabetes duration on the relationship between glycaemic control and risk of death in older adults with type 2 diabetes. Diabetes Obes Metab. 2020;22(2):231–42.PubMedCrossRef
66.
Lee AK, Warren B, Lee CJ, McEvoy JW, Matsushita K, Huang ES, et al. The association of severe hypoglycemia with Incident Cardiovascular events and mortality in adults with type 2 diabetes. Diabetes Care. 2018;41(1):104–11.PubMedCrossRef
67.
Eshaghian S, Horwich TB, Fonarow GC. An unexpected inverse relationship between HbA1c levels and mortality in patients with diabetes and advanced systolic heart failure. Am Heart J. 2006;151(1):91.PubMedCrossRef
68.
Raghavan S, Liu WG, Michael Ho P, Plomondon ME, Barón AE, Caplan L, et al. Coronary artery disease severity modifies associations between glycemic control and both mortality and myocardial infarction. J Diabetes Complications. 2018;32(5):480–7.PubMedPubMedCentralCrossRef
69.
Terry T, Raravikar K, Chokrungvaranon N, Reaven PD. Does aggressive glycemic control benefit macrovascular and microvascular disease in type 2 diabetes? Insights from ACCORD, ADVANCE, and VADT. Curr Cardiol Rep. 2012;14(1):79–88.PubMedCrossRef
70.
Takahashi H, Iwahashi N, Kirigaya J, Kataoka S, Minamimoto Y, Gohbara M, et al. Glycemic variability determined with a continuous glucose monitoring system can predict prognosis after acute coronary syndrome. Cardiovasc Diabetol. 2018;17(1):116.PubMedPubMedCentralCrossRef
71.
Besch G, Pili-Floury S, Morel C, Gilard M, Flicoteaux G, Salomon du Mont L, et al. Impact of post-procedural glycemic variability on cardiovascular morbidity and mortality after transcatheter aortic valve implantation: a post hoc cohort analysis. Cardiovasc Diabetol. 2019;18(1):27.PubMedPubMedCentralCrossRef
72.
Hashemi Madani N, Ismail-Beigi F, Khamseh ME, Malek M, Ebrahimi Valojerdi A. Predictive and explanatory factors of cardiovascular disease in people with adequately controlled type 2 diabetes. Eur J Prev Cardiol. 2017;24(11):1181–9.PubMedCrossRef
73.
Xu W, Song Q, Wang X, Zhao Z, Meng X, Xia C, et al. Association of stress hyperglycemia ratio and in-hospital mortality in patients with coronary artery disease: insights from a large cohort study. Cardiovasc Diabetol. 2022;21(1):217.PubMedPubMedCentralCrossRef
74.
Sun B, Luo Z, Zhou J. Comprehensive elaboration of glycemic variability in diabetic macrovascular and microvascular complications. Cardiovasc Diabetol. 2021;20(1):9.PubMedPubMedCentralCrossRef
75.
Gerbaud E, Darier R, Montaudon M, Beauvieux MC, Coffin-Boutreux C, Coste P, et al. Glycemic variability is a powerful independent predictive factor of Midterm Major adverse cardiac events in patients with diabetes with Acute Coronary Syndrome. Diabetes Care. 2019;42(4):674–81.PubMedCrossRef
76.
Su G, Mi SH, Tao H, Li Z, Yang HX, Zheng H, et al. Impact of admission glycemic variability, glucose, and glycosylated hemoglobin on major adverse cardiac events after acute myocardial infarction. Diabetes Care. 2013;36(4):1026–32.PubMedPubMedCentralCrossRef
77.
Tang X, Zhong J, Zhang H, Luo Y, Liu X, Peng L, et al. Visit-to-visit fasting plasma glucose variability is an important risk factor for long-term changes in left cardiac structure and function in patients with type 2 diabetes. Cardiovasc Diabetol. 2019;18(1):50.PubMedPubMedCentralCrossRef
78.
Xia J, Xu J, Hu S, Hao H, Yin C, Xu D. Impact of glycemic variability on the occurrence of periprocedural myocardial infarction and major adverse cardiovascular events (MACE) after coronary intervention in patients with stable angina pectoris at 6months follow-up. Clin Chim Acta. 2017;471:196–200.PubMedCrossRef
79.
Costantino S, Paneni F, Battista R, Castello L, Capretti G, Chiandotto S, et al. Impact of glycemic variability on chromatin remodeling, oxidative stress, and endothelial dysfunction in patients with type 2 diabetes and with target HbA(1c) levels. Diabetes. 2017;66(9):2472–82.PubMedCrossRef
80.
Yang CD, Shen Y, Lu L, Yang ZK, Hu J, Zhang RY, et al. Visit-to-visit HbA(1c) variability is associated with in-stent restenosis in patients with type 2 diabetes after percutaneous coronary intervention. Cardiovasc Diabetol. 2020;19(1):133.PubMedPubMedCentralCrossRef
81.
Shen Y, Zhou J, Shi L, Nauman E, Katzmarzyk PT, Price-Haywood EG, et al. Association between visit-to-visit HbA1c variability and the risk of cardiovascular disease in patients with type 2 diabetes. Diabetes Obes Metab. 2021;23(1):125–35.PubMedCrossRef
82.
Slieker RC, van der Heijden A, Nijpels G, Elders PJM, t Hart LM, Beulens JWJ. Visit-to-visit variability of glycemia and vascular complications: the Hoorn Diabetes Care System cohort. Cardiovasc Diabetol. 2019;18(1):170.PubMedPubMedCentralCrossRef
83.
Kilpatrick ES. The rise and fall of HbA(1c) as a risk marker for diabetes complications. Diabetologia. 2012;55(8):2089–91.PubMedCrossRef
84.
Forbes A, Murrells T, Mulnier H, Sinclair AJ. Mean HbA(1c), HbA(1c) variability, and mortality in people with diabetes aged 70 years and older: a retrospective cohort study. Lancet Diabetes Endocrinol. 2018;6(6):476–86.PubMedCrossRef
85.
Li S, Nemeth I, Donnelly L, Hapca S, Zhou K, Pearson ER. Visit-to-visit HbA(1c) variability is Associated with Cardiovascular Disease and Microvascular Complications in patients with newly diagnosed type 2 diabetes. Diabetes Care. 2020;43(2):426–32.PubMedCrossRef
86.
Qu F, Shi Q, Wang Y, Shen Y, Zhou K, Pearson ER, et al. Visit-to-visit glycated hemoglobin A1c variability in adults with type 2 diabetes: a systematic review and meta-analysis. Chin Med J (Engl). 2022;135(19):2294–300.PubMedCrossRef
87.
Monnier L, Colette C. Contributions of fasting and postprandial glucose to hemoglobin A1c. Endocr Pract. 2006;12(Suppl 1):42–6.PubMedCrossRef
88.
Jiang J, Zhao L, Lin L, Gui M, Aleteng Q, Wu B, et al. Postprandial blood glucose Outweighs Fasting Blood glucose and HbA1c in screening Coronary Heart Disease. Sci Rep. 2017;7(1):14212.PubMedPubMedCentralCrossRef
89.
Critchley JA, Carey IM, Harris T, DeWilde S, Cook DG. Variability in Glycated Hemoglobin and risk of poor outcomes among people with type 2 diabetes in a large primary care Cohort Study. Diabetes Care. 2019;42(12):2237–46.PubMedCrossRef
90.
Ceriello A, Lucisano G, Prattichizzo F, La Grotta R, Franzén S, Svensson AM, et al. HbA1c variability predicts cardiovascular complications in type 2 diabetes regardless of being at glycemic target. Cardiovasc Diabetol. 2022;21(1):13.PubMedPubMedCentralCrossRef
91.
Wan EYF, Yu EYT, Chin WY, Ng FTY, Chia SMC, Wong ICK, et al. Age-specific associations of glycated haemoglobin variability with cardiovascular disease and mortality in patients with type 2 diabetes mellitus: a 10- year cohort study. Diabetes Obes Metab. 2020;22(8):1316–27.PubMedCrossRef
92.
Hirakawa Y, Arima H, Zoungas S, Ninomiya T, Cooper M, Hamet P, et al. Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial. Diabetes Care. 2014;37(8):2359–65.PubMedCrossRef
93.
Sun B, Gao Y, He F, Liu Z, Zhou J, Wang X, et al. Association of visit-to-visit HbA1c variability with cardiovascular diseases in type 2 diabetes within or outside the target range of HbA1c. Front Public Health. 2022;10:1052485.PubMedPubMedCentralCrossRef
94.
Penno G, Solini A, Zoppini G, Orsi E, Fondelli C, Zerbini G, et al. Hemoglobin A1c variability as an independent correlate of cardiovascular disease in patients with type 2 diabetes: a cross-sectional analysis of the renal insufficiency and cardiovascular events (RIACE) italian multicenter study. Cardiovasc Diabetol. 2013;12:98.PubMedPubMedCentralCrossRef
95.
Yang Y, Lee EY, Cho JH, Park YM, Ko SH, Yoon KH, et al. Cardiovascular Autonomic Neuropathy predicts higher HbA1c variability in subjects with type 2 diabetes Mellitus. Diabetes Metab J. 2018;42(6):496–512.PubMedPubMedCentralCrossRef
96.
Lee MY, Hsiao PJ, Huang YT, Huang JC, Hsu WH, Chen SC, et al. Greater HbA1c variability is associated with increased cardiovascular events in type 2 diabetes patients with preserved renal function, but not in moderate to advanced chronic kidney disease. PLoS ONE. 2017;12(6):e0178319.PubMedPubMedCentralCrossRef
97.
Yang HK, Kang B, Lee SH, Yoon KH, Hwang BH, Chang K, et al. Association between hemoglobin A1c variability and subclinical coronary atherosclerosis in subjects with type 2 diabetes. J Diabetes Complications. 2015;29(6):776–82.PubMedCrossRef
98.
Langlois MR, Delanghe JR. Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem. 1996;42(10):1589–600.PubMedCrossRef
99.
Jensen MK, Bertoia ML, Cahill LE, Agarwal I, Rimm EB, Mukamal KJ. Novel metabolic biomarkers of cardiovascular disease. Nat Rev Endocrinol. 2014;10(11):659–72.PubMedCrossRef
100.
Delanghe JR, Langlois MR. Hemopexin: a review of biological aspects and the role in laboratory medicine. Clin Chim Acta. 2001;312(1–2):13–23.PubMedCrossRef
101.
Carter K, Worwood M. Haptoglobin: a review of the major allele frequencies worldwide and their association with diseases. Int J Lab Hematol. 2007;29(2):92–110.PubMedCrossRef
102.
Levy AP, Asleh R, Blum S, Levy NS, Miller-Lotan R, Kalet-Litman S, et al. Haptoglobin: basic and clinical aspects. Antioxid Redox Signal. 2010;12(2):293–304.PubMedCrossRef
103.
Suzuki K, Yagi K, Oka R, Saiki Y, Kubota M, Sugihara M, et al. Relationships of serum haptoglobin concentration with HbA1c and glycated albumin concentrations in japanese type 2 diabetic patients. Clin Chem Lab Med. 2009;47(1):70–4.PubMedCrossRef
104.
Gutteridge JM. The antioxidant activity of haptoglobin towards haemoglobin-stimulated lipid peroxidation. Biochim Biophys Acta. 1987;917(2):219–23.PubMedCrossRef
105.
Andersen CBF, Stødkilde K, Sæderup KL, Kuhlee A, Raunser S, Graversen JH, et al. Haptoglobin Antioxid Redox Signal. 2017;26(14):814–31.PubMedCrossRef
106.
Högger P, Dreier J, Droste A, Buck F, Sorg C. Identification of the integral membrane protein RM3/1 on human monocytes as a glucocorticoid-inducible member of the scavenger receptor cysteine-rich family (CD163). J Immunol. 1998;161(4):1883–90.PubMedCrossRef
107.
Asleh R, Levy AP. In vivo and in vitro studies establishing haptoglobin as a major susceptibility gene for diabetic vascular disease. Vasc Health Risk Manag. 2005;1(1):19–28.PubMedPubMedCentralCrossRef
108.
Asleh R, Marsh S, Shilkrut M, Binah O, Guetta J, Lejbkowicz F, et al. Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circ Res. 2003;92(11):1193–200.PubMedCrossRef
109.
Asleh R, Guetta J, Kalet-Litman S, Miller-Lotan R, Levy AP. Haptoglobin genotype- and diabetes-dependent differences in iron-mediated oxidative stress in vitro and in vivo. Circ Res. 2005;96(4):435–41.PubMedCrossRef
110.
Asleh R, Miller-Lotan R, Aviram M, Hayek T, Yulish M, Levy JE, et al. Haptoglobin genotype is a regulator of reverse cholesterol transport in diabetes in vitro and in vivo. Circ Res. 2006;99(12):1419–25.PubMedCrossRef
111.
Asleh R, Blum S, Kalet-Litman S, Alshiek J, Miller-Lotan R, Asaf R, et al. Correction of HDL dysfunction in individuals with diabetes and the haptoglobin 2–2 genotype. Diabetes. 2008;57(10):2794–800.PubMedPubMedCentralCrossRef
112.
Melamed-Frank M, Lache O, Enav BI, Szafranek T, Levy NS, Ricklis RM, et al. Structure-function analysis of the antioxidant properties of haptoglobin. Blood. 2001;98(13):3693–8.PubMedCrossRef
113.
Bamm VV, Tsemakhovich VA, Shaklai M, Shaklai N. Haptoglobin phenotypes differ in their ability to inhibit heme transfer from hemoglobin to LDL. Biochemistry. 2004;43(13):3899–906.PubMedCrossRef
114.
Guetta J, Strauss M, Levy NS, Fahoum L, Levy AP. Haptoglobin genotype modulates the balance of Th1/Th2 cytokines produced by macrophages exposed to free hemoglobin. Atherosclerosis. 2007;191(1):48–53.PubMedCrossRef
115.
Mody P, Joshi PH, Khera A, Ayers CR, Rohatgi A. Beyond coronary calcification, Family History, and C-Reactive protein: cholesterol Efflux Capacity and Cardiovascular Risk Prediction. J Am Coll Cardiol. 2016;67(21):2480–7.PubMedPubMedCentralCrossRef
116.
Matuschik L, Riabov V, Schmuttermaier C, Sevastyanova T, Weiss C, Klüter H et al. Hyperglycemia induces inflammatory response of human macrophages to CD163-Mediated scavenging of hemoglobin-haptoglobin complexes. Int J Mol Sci. 2022;23(3).
117.
Suleiman M, Aronson D, Asleh R, Kapeliovich MR, Roguin A, Meisel SR, et al. Haptoglobin polymorphism predicts 30-day mortality and heart failure in patients with diabetes and acute myocardial infarction. Diabetes. 2005;54(9):2802–6.PubMedCrossRef
118.
Levy AP, Roguin A, Hochberg I, Herer P, Marsh S, Nakhoul FM, et al. Haptoglobin phenotype and vascular complications in patients with diabetes. N Engl J Med. 2000;343(13):969–70.PubMedCrossRef
119.
Levy AP, Hochberg I, Jablonski K, Resnick HE, Lee ET, Best L, et al. Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: the strong heart study. J Am Coll Cardiol. 2002;40(11):1984–90.PubMedCrossRef
120.
Cahill LE, Levy AP, Chiuve SE, Jensen MK, Wang H, Shara NM, et al. Haptoglobin genotype is a consistent marker of coronary heart disease risk among individuals with elevated glycosylated hemoglobin. J Am Coll Cardiol. 2013;61(7):728–37.PubMedPubMedCentralCrossRef
121.
Cahill LE, Jensen MK, Chiuve SE, Shalom H, Pai JK, Flint AJ, et al. The risk of Coronary Heart Disease Associated with glycosylated hemoglobin of 6.5% or Greater is Pronounced in the haptoglobin 2–2 genotype. J Am Coll Cardiol. 2015;66(16):1791–9.PubMedPubMedCentralCrossRef
122.
Pechlaner R, Kiechl S, Willeit P, Demetz E, Haun M, Weger S, et al. Haptoglobin 2–2 genotype is not associated with cardiovascular risk in subjects with elevated glycohemoglobin-results from the Bruneck Study. J Am Heart Assoc. 2014;3(3):e000732.PubMedPubMedCentralCrossRef
123.
De Bacquer D, De Backer G, Langlois M, Delanghe J, Kesteloot H, Kornitzer M. Haptoglobin polymorphism as a risk factor for coronary heart disease mortality. Atherosclerosis. 2001;157(1):161–6.PubMedCrossRef
124.
Levy AP, Larson MG, Corey D, Lotan R, Vita JA, Benjamin EJ. Haptoglobin phenotype and prevalent coronary heart disease in the Framingham offspring cohort. Atherosclerosis. 2004;172(2):361–5.PubMedCrossRef
125.
Gurung RL, Yiamunaa M, Liu S, Liu JJ, Chan C, Choo RWM, et al. Association of haptoglobin phenotype with incident acute myocardial infarction in chinese patients with type 2 diabetes. Cardiovasc Diabetol. 2019;18(1):65.PubMedPubMedCentralCrossRef
126.
Wang S, Wang J, Zhang R, Wang T, Yan D, He Z, et al. Mendelian randomization analysis to assess a causal effect of haptoglobin on macroangiopathy in chinese type 2 diabetes patients. Cardiovasc Diabetol. 2018;17(1):14.PubMedPubMedCentralCrossRef
127.
Warren RA, Carew AS, Andreou P, Herman C, Levy AP, Ginsberg HN, et al. Haptoglobin phenotype modifies the Effect of Fenofibrate on risk of coronary event: ACCORD lipid trial. Diabetes Care. 2022;45(1):241–50.PubMedCrossRef
128.
Napolioni V, Giannì P, Carpi FM, Concetti F, Lucarini N. Haptoglobin (HP) polymorphisms and human longevity: a cross-sectional association study in a Central Italy population. Clin Chim Acta. 2011;412(7–8):574–7.PubMedCrossRef
129.
Sudmant PH, Mallick S, Nelson BJ, Hormozdiari F, Krumm N, Huddleston J, et al. Global diversity, population stratification, and selection of human copy-number variation. Science. 2015;349(6253):aab3761.PubMedPubMedCentralCrossRef
130.
Carew AS, Levy AP, Ginsberg HN, Coca S, Lache O, Ransom T, et al. Haptoglobin phenotype modifies the influence of Intensive Glycemic Control on Cardiovascular Outcomes. J Am Coll Cardiol. 2020;75(5):512–21.PubMedCrossRef
131.
Morieri ML, Shah HS, Tang Y, Doria A. Insufficient evidence for Interaction between Haptoglobin Phenotypes and Intensive Glycemic Control on Cardiovascular Outcomes. J Am Coll Cardiol. 2020;75(23):2995–6.PubMedCrossRef
132.
Drucker DJ, Habener JF, Holst JJ. Discovery, characterization, and clinical development of the glucagon-like peptides. J Clin Invest. 2017;127(12):4217–27.PubMedPubMedCentralCrossRef
133.
Gupta NA, Mells J, Dunham RM, Grakoui A, Handy J, Saxena NK, et al. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology. 2010;51(5):1584–92.PubMedCrossRef
134.
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and Cardiovascular Outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22.PubMedPubMedCentralCrossRef
135.
Verma S, Bain SC, Buse JB, Idorn T, Rasmussen S, Ørsted DD, et al. Occurence of First and recurrent major adverse Cardiovascular events with Liraglutide Treatment among patients with type 2 diabetes and high risk of Cardiovascular events: a Post Hoc Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2019;4(12):1214–20.PubMedCrossRef
136.
Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, et al. Cardiovascular and renal outcomes with Efpeglenatide in Type 2 diabetes. N Engl J Med. 2021;385(10):896–907.PubMedCrossRef
137.
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121–30.PubMedCrossRef
138.
Dagenais GR, Rydén L, Leiter LA, Lakshmanan M, Dyal L, Probstfield JL, et al. Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis. Cardiovasc Diabetol. 2020;19(1):199.PubMedPubMedCentralCrossRef
139.
Konig M, Riddle MC, Colhoun HM, Branch KR, Atisso CM, Lakshmanan MC, et al. Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND. Cardiovasc Diabetol. 2021;20(1):194.PubMedPubMedCentralCrossRef
140.
Buse JB, Bain SC, Mann JFE, Nauck MA, Nissen SE, Pocock S, et al. Cardiovascular Risk Reduction with Liraglutide: an exploratory mediation analysis of the LEADER Trial. Diabetes Care. 2020;43(7):1546–52.PubMedPubMedCentralCrossRef
141.
Brown-Frandsen K, Emerson SS, McGuire DK, Pieber TR, Poulter NR, Pratley RE, et al. Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: a DEVOTE subanalysis (DEVOTE 10). Diabetes Obes Metab. 2019;21(6):1437–44.PubMedPubMedCentralCrossRef
142.
Warren M, Chaykin L, Trachtenbarg D, Nayak G, Wijayasinghe N, Cariou B. Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: pooled analysis of the SUSTAIN 1–5 trials. Diabetes Obes Metab. 2018;20(9):2291–7.PubMedPubMedCentralCrossRef
143.
Wang W, Nevárez L, Filippova E, Song KH, Tao B, Gu L, et al. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in mainly asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: a 52-week open-label, randomized phase III trial. Diabetes Obes Metab. 2019;21(2):234–43.PubMedCrossRef
144.
Nathan DM, Lachin JM, Bebu I, Burch HB, Buse JB, Cherrington AL, et al. Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes. N Engl J Med. 2022;387(12):1075–88.PubMedCrossRef
145.
Frias JP, Choi J, Rosenstock J, Popescu L, Niemoeller E, Muehlen-Bartmer I, et al. Efficacy and safety of once-weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 diabetes: the AMPLITUDE-M randomized controlled trial. Diabetes Care. 2022;45(7):1592–600.PubMedPubMedCentralCrossRef
146.
Ludvik B, Giorgino F, Jódar E, Frias JP, Fernández Landó L, Brown K, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021;398(10300):583–98.PubMedCrossRef
147.
Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015;75(1):33–59.PubMedCrossRef
148.
Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes Mellitus: Cardiovascular and kidney Effects, potential mechanisms, and clinical applications. Circulation. 2016;134(10):752–72.PubMedCrossRef
149.
Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with Empagliflozin in Heart failure. N Engl J Med. 2020;383(15):1413–24.PubMedCrossRef
150.
Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–306.PubMedCrossRef
151.
Fitchett D, Inzucchi SE, Cannon CP, McGuire DK, Scirica BM, Johansen OE, et al. Empagliflozin reduced mortality and hospitalization for heart failure across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial. Circulation. 2019;139(11):1384–95.PubMedCrossRef
152.
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.PubMedCrossRef
153.
Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and Cardiovascular Outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–57.PubMedCrossRef
154.
Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31–9.PubMedCrossRef
155.
Furtado RHM, Bonaca MP, Raz I, Zelniker TA, Mosenzon O, Cahn A, et al. Dapagliflozin and Cardiovascular Outcomes in patients with type 2 diabetes Mellitus and previous myocardial infarction. Circulation. 2019;139(22):2516–27.PubMedCrossRef
156.
McGuire DK, Zinman B, Inzucchi SE, Wanner C, Fitchett D, Anker SD, et al. Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial. Lancet Diabetes Endocrinol. 2020;8(12):949–59.PubMedCrossRef
157.
Leccisotti L, Cinti F, Sorice GP, D’Amario D, Lorusso M, Guzzardi MA, et al. Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report. Cardiovasc Diabetol. 2022;21(1):173.PubMedPubMedCentralCrossRef
158.
Ceriello A, Ofstad AP, Zwiener I, Kaspers S, George J, Nicolucci A. Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial. Cardiovasc Diabetol. 2020;19(1):176.PubMedPubMedCentralCrossRef
159.
Cahn A, Wiviott SD, Mosenzon O, Goodrich EL, Murphy SA, Yanuv I, et al. Association of Baseline HbA1c with Cardiovascular and renal outcomes: analyses from DECLARE-TIMI 58. Diabetes Care. 2022;45(4):938–46.PubMedCrossRef
160.
Young TK, Li JW, Kang A, Heerspink HJL, Hockham C, Arnott C, et al. Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA(1c), disease duration and treatment intensity: results from the CANVAS Program. Diabetologia. 2021;64(11):2402–14.PubMedPubMedCentralCrossRef
161.
McCarter RJ, Hempe JM, Gomez R, Chalew SA. Biological variation in HbA1c predicts risk of retinopathy and nephropathy in type 1 diabetes. Diabetes Care. 2004;27(6):1259–64.PubMedCrossRef
162.
Ahn CH, Min SH, Lee DH, Oh TJ, Kim KM, Moon JH, et al. Hemoglobin glycation index is Associated with Cardiovascular Diseases in people with impaired glucose metabolism. J Clin Endocrinol Metab. 2017;102(8):2905–13.PubMedPubMedCentralCrossRef
163.
Rezende PC, Hlatky MA, Hueb W, Garcia RMR, da Silva Selistre L, Lima EG, et al. Association of Longitudinal values of Glycated Hemoglobin with Cardiovascular events in patients with diabetes and Multivessel Coronary Artery Disease. JAMA Netw Open. 2020;3(1):e1919666.PubMedPubMedCentralCrossRef
164.
Elhadd T, Mall R, Bashir M, Palotti J, Fernandez-Luque L, Farooq F, et al. Artificial Intelligence (AI) based machine learning models predict glucose variability and hypoglycaemia risk in patients with type 2 diabetes on a multiple drug regimen who fast during ramadan (the PROFAST - IT Ramadan study). Diabetes Res Clin Pract. 2020;169:108388.PubMedCrossRef
165.
Cahn A, Zuker I, Eilenberg R, Uziel M, Tsadok MA, Raz I, et al. Machine learning based study of longitudinal HbA1c trends and their association with all-cause mortality: analyses from a National Diabetes Registry. Diabetes Metab Res Rev. 2022;38(1):e3485.PubMedCrossRef
166.
Leong A, Chen J, Wheeler E, Hivert MF, Liu CT, Merino J, et al. Mendelian randomization analysis of Hemoglobin A(1c) as a risk factor for coronary artery disease. Diabetes Care. 2019;42(7):1202–8.PubMedPubMedCentralCrossRef
167.
Campbell L, Pepper T, Shipman K. HbA1c: a review of non-glycaemic variables. J Clin Pathol. 2019;72(1):12–9.PubMedCrossRef
168.
Levy NS, Vardi M, Blum S, Miller-Lotan R, Afinbinder Y, Cleary PA, et al. An enzyme linked immunosorbent assay (ELISA) for the determination of the human haptoglobin phenotype. Clin Chem Lab Med. 2013;51(8):1615–22.PubMedPubMedCentralCrossRef
169.
Quaye IK, Ababio G, Amoah AG. Haptoglobin 2–2 phenotype is a risk factor for type 2 diabetes in Ghana. J Atheroscler Thromb. 2006;13(2):90–4.PubMedCrossRef
Metadata
Title
Intensified glycemic control by HbA1c for patients with coronary heart disease and Type 2 diabetes: a review of findings and conclusions
Authors
Jingyang Chen
Dong Yin
Kefei Dou
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2023
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-023-01875-8

Other articles of this Issue 1/2023

Cardiovascular Diabetology 1/2023 Go to the issue

Research

Insulin growth factor axis and cardio-renal risk in diabetic kidney disease: an analysis from the CREDENCE trial

Research

Impact of chronic GLP-1 RA and SGLT-2I therapy on in-hospital outcome of diabetic patients with acute myocardial infarction

Research

Insulin resistance estimated by estimated glucose disposal rate predicts outcomes in acute ischemic stroke patients

Research

Multi-trajectories of triglyceride-glucose index and lifestyle with Cardiovascular Disease: a cohort study

Research

Intravenous ferric carboxymaltose for iron repletion following acute heart failure in patients with and without diabetes: a subgroup analysis of the randomized AFFIRM-AHF trial

Research

The joint association of diabetes status and NT-ProBNP with adverse cardiac outcomes in patients with non-ST-segment elevation acute coronary syndrome: a prospective cohort study
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits